Elevated levels of proliferating and recently migrated tumor-associated macrophages confer increased aggressiveness and worse outcomes in breast cancer

Annals of Surgical Oncology

Volumn 19, Issue 12, 2012, Pages 3979-3986

  Mukhtar, Rita A ^a   Moore, Amy P ^a   Tandon, Vickram J ^a   Nseyo, Onouwem ^a   Twomey, Patrick ^a   Adisa, Charles Adeyinka ^b   Eleweke, Ndukauba ^a   Au, Alfred ^a   Baehner, Frederick L ^c   Moore, Dan H ^a   McGrath, Michael S ^c   Olopade, Olofunmilayo I ^d   Gray, Joe W ^e   Campbell, Michael J ^a   Esserman, Laura J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ABIA STATE UNIVERSITY   (Nigeria)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e Oregon Health and Science University Department of Biomedical Engineering   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN A; CALGRANULIN B;

ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER RECURRENCE; CELL PROLIFERATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MACROPHAGE MIGRATION; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CALGRANULIN A; CALGRANULIN B; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MACROPHAGES; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84868035962     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2415-2     Document Type: Article

References (55)

1. Eubank TD, Galloway M, Montague CM, Waldman WJ, Marsh CB. M-CSF induces vascular endothelial growth factor production and angiogenic activity from human monocytes. J Immunol. 2003;171:2637-43. (Pubitemid 37025577)
2. Lewis CE, Leek R, Harris A, McGee JO. Cytokine regulation of angiogenesis in breast cancer: the role of tumor-associated macrophages. J Leukoc Biol. 1995;57:747-51.
3. Lin EY, Pollard JW. Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res. 2007;67:5064-6. (Pubitemid 46997238)
4. Lin EY, Li JF, Gnatovskiy L, et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 2006;66:11238-46. (Pubitemid 46009952)
5. Talmadge JE, Donkor M, Scholar E. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev. 2007;26:373-400. (Pubitemid 350115102)
6. Chang YC, Chen TC, Lee CT, et al. Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3. Blood. 2008;111:5054-63.
7. Van Ginderachter JA, Movahedi K, Hassanzadeh Ghassabeh G, et al. Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion. Immunobiology. 2006;211:487-501.
8. Mosser DM. The many faces of macrophage activation. J Leukoc Biol. 2003;73:209-12. (Pubitemid 36158295)
9. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8:958-69.
10. Evans R, Cullen RT. In situ proliferation of intratumor macrophages. J Leukoc Biol. 1984;35:561-72. (Pubitemid 14051753)
11. Stewart CC. Local proliferation of mononuclear phagocytes in tumors. J Reticuloendothel Soc. 1983;34:23-7. (Pubitemid 13012980)
12. Stewart CC, Beetham KL. Cytocidal activity and proliferative ability of macrophages infiltrating the EMT6 tumor. Int J Cancer. 1978;22:152-9. (Pubitemid 8398214)
13. Gottfried E, Kunz-Schughart LA, Weber A, et al. Expression of CD68 in non-myeloid cell types. Scand J Immunol. 2008;67: 453-63. (Pubitemid 351519391)
14. Leonardi E, Girlando S, Serio G, et al. PCNA and Ki67 expression in breast carcinoma: correlations with clinical and biological variables. J Clin Pathol. 1992;45:416-9.
15. Campbell MJ, Tonlaar NY, Garwood ER, et al. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat. 2011;128:703-11.
16. Isbel NM, Nikolic-Paterson DJ, Hill PA, Dowling J, Atkins RC. Local macrophage proliferation correlates with increased renal M-CSF expression in human glomerulonephritis. Nephrol Dial Transplant. 2001;16:1638-47. (Pubitemid 32750457)
17. Shiomi M, Yamada S, Ito T. Atheroma stabilizing effects of simvastatin due to depression of macrophages or lipid accumulation in the atheromatous plaques of coronary plaque-prone WHHL rabbits. Atherosclerosis. 2005;178:287-94. (Pubitemid 40193442)
18. Fischer-Smith T, Croul S, Adeniyi A, et al. Macrophage/microglial accumulation and proliferating cell nuclear antigen expression in the central nervous system in human immunodeficiency virus encephalopathy. Am J Pathol. 2004;164:2089-99. (Pubitemid 38669356)
19. Zenger E, Abbey NW, Weinstein MD, et al. Injection of human primary effusion lymphoma cells or associated macrophages into severe combined immunodeficient mice causes murine lymphomas. Cancer Res. 2002;62:5536.
20. Liu J, Li Z, Cui J, Xu G, Cui G. Cellular changes in the tumor microenvironment of human esophageal squamous cell carcinomas. Tumour Biol. 2012;33:495-505.
21. Arai K, Takano S, Teratani T, Ito Y, Yamada T, Nozawa R. S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast. Curr Cancer Drug Targets. 2008;8:243-52. (Pubitemid 351881350)
22. Subimerb C, Pinlaor S, Lulitanond V, et al. Circulating CD14(+) CD16(+) monocyte levels predict tissue invasive character of cholangiocarcinoma. Clin Exp Immunol. 2010;161:471-9.
23. Gebhardt C, Breitenbach U, Tuckermann JP, Dittrich BT, Richter KH, Angel P. Calgranulins S100A8 and S100A9 are negatively regulated by glucocorticoids in a c-Fos-dependent manner and overexpressed throughout skin carcinogenesis. Oncogene. 2002; 21:4266-76. (Pubitemid 34753833)
24. Kim HJ, Kang HJ, Lee H, et al. Identification of S100A8 and S100A9 as serological markers for colorectal cancer. J Proteome Res. 2009;8:1368-79.
25. Hermani A, Hess J, De Servi B, et al. Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin Cancer Res. 2005;11:5146-52. (Pubitemid 41003699)
26. Chin K, DeVries S, Fridlyand J, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 2006;10:529-41. (Pubitemid 44854748)
27. Mukhtar R, Moore A, Nseyo O, et al. Evaluation of levels of proliferating macrophages in patients at a county hospital and those with early recurrences. J Clin Oncol. 2010;28(15 Suppl): 1110.
28. Huo D, Ikpatt F, Khramtsov A, et al. Population differences in breast cancer: survey in indigenous African women reveals overrepresentation of triple-negative breast cancer. J Clin Oncol. 2009;27:4515-21.
29. Mukhtar RA, Moore AP, Nseyo O, et al. Elevated PCNA? tumorassociated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity. Breast Cancer Res Treat. 2011;130:635-44.
30. Shabo I, Stal O, Olsson H, Dore S, Svanvik J. Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival. Int J Cancer. 2008;123:780-6. (Pubitemid 352032402)
31. Shabo I, Svanvik J. Expression of macrophage antigens by tumor cells. Adv Exp Med Biol. 2011;714:141-50.
32. Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol. 2008;66:1-9. (Pubitemid 351324128)
33. Fujimoto H, Sangai T, Ishii G, et al. Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression. Int J Cancer. 2009;125:1276-84.
34. Eubank TD, Roberts RD, Khan M, et al. Granulocyte macrophage colony-stimulating factor inhibits breast cancer growth and metastasis by invoking an anti-angiogenic program in tumoreducated macrophages. Cancer Res. 2009;69:2133-40.
35. Lin EY, Pollard JW. Macrophages: modulators of breast cancer progression. Novartis Found Symp. 2004;256:158-68.
36. Sinha P, Clements VK, Miller S, Ostrand-Rosenberg S. Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression. Cancer Immunol Immunother. 2005;54:1137-42. (Pubitemid 41396817)
37. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol. 2007;179:977-83.
38. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25:677-86. (Pubitemid 39457982)
39. DeNardo DG, Barreto JB, Andreu P, et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell. 2009;16:91-102.
40. Laoui D, Movahedi K, Van Overmeire E, et al. Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions. Int J Dev Biol. 2011;55:861-7.
41. Volodko NRA, Rudas M, Jakesz R. Tumour-associated macrophages in breast cancer and their prognostic correlations. Breast. 1998;7:99-105. (Pubitemid 28230834)
42. Leek RD, Landers RJ, Harris AL, Lewis CE. Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer. 1999;79:991-5. (Pubitemid 29082138)
43. Balkwill F, Mantovani A. Cancer and inflammation: implications for pharmacology and therapeutics. Clin Pharmacol Ther. 2010;87:401-6.
44. Patsialou A, Wyckoff J, Wang Y, Goswami S, Stanley ER, Condeelis JS. Invasion of human breast cancer cells in vivo requires both paracrine and autocrine loops involving the colonystimulating factor-1 receptor. Cancer Res. 2009;69:9498-506.
45. Ehrchen JM, Sunderkotter C, Foell D, Vogl T, Roth J. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol. 2009;86:557-66.
46. Manitz MP, Horst B, Seeliger S, et al. Loss of S100A9 (MRP14) results in reduced interleukin-8-induced CD11b surface expression, a polarized microfilament system, and diminished responsiveness to chemoattractants in vitro. Mol Cell Biol. 2003;23: 1034-43. (Pubitemid 36133519)
47. Vogl T, Ludwig S, Goebeler M, et al. MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes. Blood. 2004;104:4260-8. (Pubitemid 39620181)
48. Buckner CM, Calderon TM, Willams DW, Belbin TJ, Berman JW. Characterization of monocyte maturation/differentiation that facilitates their transmigration across the blood-brain barrier and infection by HIV: implications for NeuroAIDS. Cell Immunol. 2011;267:109-23.
49. McKiernan E, McDermott EW, Evoy D, Crown J, Duffy MJ. The role of S100 genes in breast cancer progression. Tumour Biol. 2011;32:441-50.
50. Gebhardt C, Nemeth J, Angel P, Hess J. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol. 2006;72:1622-31. (Pubitemid 44666730)
51. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumorinduced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev. 2008;222:162-79. (Pubitemid 351430364)
52. Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol. 2008;181: 4666-75.
53. Pawelek JM. Cancer-cell fusion with migratory bone-marrowderived cells as an explanation for metastasis: new therapeutic paradigms. Future Oncol. 2008;4:449-52.
54. Pawelek JM. Tumour-cell fusion as a source of myeloid traits in cancer. Lancet Oncol. 2005;6:988-93. (Pubitemid 41685232)
55. Pawelek JM, Chakraborty AK. Fusion of tumour cells with bone marrow-derived cells: a unifying explanation for metastasis. Nat Rev Cancer. 2008;8:377-86. (Pubitemid 351589699)